 Home > Active Ingredient News > Antitumor Therapy > Thorac Cancer: Efficacy of crizotinib-alatinib continuous regimen in the treatment of Chinese patients with advanced ALK-positive NSCLC

Thorac Cancer: Efficacy of crizotinib-alatinib continuous regimen in the treatment of Chinese patients with advanced ALK-positive NSCLC

 Last Update: 2021-12-25
 Source: Internet
 Author: User

Tags

5 8 inch

1 6 hexanediol

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

At present , patients with advanced ALK-positive non-small cell lung cancer ( NSCLC ) in China are treated with crizotinib as the first-line treatment.

The study included patients treated with the continuous crizotinib-alatinib regimen from 6 centers in China

The study included 61 patients

Efficacy of crizotinib treatment: 60 cases can be evaluated with an ORR of 60% (1CR + 35PR); and patients with target lesions have an ORR of 85.

The median PFS of crizotinib-resistant patients (n = 52) was 15.

Prognosis of Crizotinib

Efficacy of aletinib treatment: 52 patients, ORR was 47.

Efficacy of Tinib Efficacy of Tinib

The PFS of crizotinib-resistant patients during atinib treatment was 13.

Prognosis of Aletinib

The median OS of crizotinib-resistant patients (n = 52) has not yet been reached
.
The 3-year, 4-year, and 5-year OS rates were 85.
4% (95% CI: 71.
6%-92.
8%), 73.
6% (95% CI: 54.
6%-85.
7%), and 66.
7% (95%CI: 44.
6%), respectively –81.
9%)
.
The 3-year, 4-year, and 5-year OS rates of patients in the overall population were 87.
1% (95% CI: 74.
5%–93.
7%), 75.
4% (95% CI: 56.
7%–86.
9%), and 68.
6% (95% CI), respectively : 46.
0%–83.
2%)
.
The C-TTF was 39.
2 months (95% CI: 30.
0-49.
6)
.
The median OS of crizotinib-resistant patients (n = 52) has not yet been reached
.
The 3-year, 4-year, and 5-year OS rates were 85.
4% (95% CI: 71.
6%-92.
8%), 73.
6% (95% CI: 54.
6%-85.
7%), and 66.
7% (95%CI: 44.
6%), respectively –81.
9%)
.
The 3-year, 4-year, and 5-year OS rates of patients in the overall population were 87.
1% (95% CI: 74.
5%–93.
7%), 75.
4% (95% CI: 56.
7%–86.
9%), and 68.
6% (95% CI), respectively : 46.
0%–83.
2%)
.
The C-TTF was 39.
2 months (95% CI: 30.
0-49.
6)
.

OS and C-TTF

OS and C-TTF OS and C-TTF

In summary, studies have shown that first-line crizotinib and second-line aletinib can bring long-term survival benefits to Chinese patients with advanced ALK+NSCLC
.

In summary, studies have shown that first-line crizotinib and second-line aletinib can bring long-term survival benefits to Chinese patients with advanced ALK+NSCLC
.
Studies have shown that first-line crizotinib followed by second-line aletinib brings long-term survival benefits to Chinese patients with advanced ALK+NSCLC
.
Studies have shown that first-line crizotinib followed by second-line aletinib brings long-term survival benefits to Chinese patients with advanced ALK+NSCLC
.

Original source:

Zou Z, Hao X, Zhang C, et al.
Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Thorac Cancer.
2021 Dec 1.
doi: 10.
1111/1759-7714.
14232.
Epub ahead of print.
PMID: 34851035.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.